Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 13 hours ago

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Bristol Myers Squibb (BMY -0.91%) primarily generates its revenue by developing and selling prescription therapeutic medications for oncology and cardiovascular health worldwide.

The Motley Fool • 17 hours ago

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.

Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.

The Motley Fool • 17 hours ago

Bristol Myers Squibb vs. Pfizer: Consistency vs.

Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth.

The Motley Fool • 6 hours ago

Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.

Zacks Investment Research • Oct 21, 2026

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?

AbbVie currently looks stronger on revenue by consistently generating higher overall totals and demonstrating a faster growth trajectory across the measured periods. Both companies record quarter-over-quarter declines at the start of the year, but they maintain generally upward trajectories over the last eight quarters, with AbbVie showing wider increases.

The Motley Fool • Oct 21, 2026

Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings

On October 27, Bristol-Myers Squibb will report its results for Q3. As a reminder, its Q2 revenue rose 12.9% quarter-on-quarter to $12.97 billion, primarily due to the strong performance of Camzyos and the oncology portfolio. On October 12, BMS reported that Phase 3 ACTION-1 met its primary endpoint, significantly improving PFS with RYZ101 in SSTR+ GEP-NET patients.

Seeking Alpha • Oct 21, 2026

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.

24/7 Wall Street • Oct 20, 2026

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is demonstrating strong top-line growth driven by a diverse portfolio in oncology and rare diseases. Bristol Myers Squibb remains a heavy producer of free cash flow while offering a significantly lower valuation.

The Motley Fool • Oct 20, 2026

15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now

Rose's Income Garden portfolio review highlights 15 most undervalued and 15 most overvalued dividend stocks using 52-week high/low analysis. Energy names like XOM, SHEL, and CVX have rotated into overvalued territory, while high-yield REITs such as VICI remain top undervalued picks. Dividend yield remains a key selection criterion, with several undervalued stocks offering yields above 5% and investment-grade credit ratings.

Seeking Alpha • Oct 20, 2026